2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, (CAR)-T Cell Therapies, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Adverse Events, Biological Processes, Apoptosis, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Research, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1535 Using neonatal immune profiles to distinguish children with down syndrome who develop acute lymphoblastic leukemia (ALL)

Michael Scheurer, MPH, PhD, FACE, Chris Belz2, Caroline Shi, MPH3, Shixia Huang, PhD4, Zhongcheng Shi, PhD5, Karen R. Rabin, MD, PhD6, Adam J de Smith, PhD7, Philip J. Lupo, PhD, MPH8
1 Childrens Healthcare of Atlanta, Atlanta, Georgia, United States, Emory University School of Medicine, Atlanta, Georgia, United States
2 Emory University School of Medicine, Atlanta, Georgia, United States
3 Emory University School of Medicine, Atlanta, Georgia, United States
4 Baylor College of Medicine, Houston, Texas, United States
5 Baylor College of Medicine, Houston, Texas, United States
6 UCSF Benioff Children's Hospitals, San Francisco, California, United States, University of California, San Francisco, San Francisco, California, United States
7 City of Hope Comprehensive Cancer Center, Duarte, California, United States
8 Childrens Healthcare of Atlanta, Atlanta, Georgia, United States, Emory University School of Medicine, Atlanta, Georgia, United States

Background and Aims: Children born with Down syndrome (DS) are 20-times more likely to develop acute lymphoblastic leukemia ALL (i.e., DS-ALL) compared to those without DS. While the underlying causes remain largely unknown, it has been hypothesized that immune dysregulation could contribute to risk. This study evaluates associations between neonatal immune biomarker levels and DS-ALL.

Methods: We conducted a case-control analysis comparing immune markers extracted from neonatal blood spots (NBS) from cases with DS-ALL compared to controls with DS without ALL. Cases and controls were identified by linking the Michigan Neonatal Biobank to the Michigan Cancer Surveillance Program. Multiple controls were pair-matched to cases based on race/ethnicity, sex, and birth year. Proteins were extracted from NBS using a modified protocol, and a panel of 80 cytokines/chemokines was quantified using a Luminex bead-based multiplex assay following the manufacturer’s standard instructions. Analytes with values below the minimum detectable level (MDL) for >25% of cases and/or controls were excluded from further analysis, and remaining analyte measures below the MDL were imputed as one-half of the MDL for that analyte and plate experiment. Measurements were log2-transformed and included as a transformed continuous variable in conditional logistic regression models for each analyte.

Results: We included 118 children with DS in our analysis (n=25 cases and n=93 controls). After exclusions based on values below the MDL and between plate batch effects,14 analytes were evaluated in conditional logistic regression models; one was significantly associated with DS-ALL after Bonferroni correction (VEGF-A) while an additional four were nominally significant (IL-8, GRO-Alpha, IP-10 and MCP-1) and one was borderline (MIF, p=0.051). Effect sizes ranged from 1.61-3.05 per unit increase in the log increase of cytokine level.

Conclusions: These findings suggest that pro-inflammatory cytokine signaling pathways are over-expressed at birth among children with DS who go on to develop ALL. This suggests the potential for improved screening and risk stratification, though further research is necessary.

Michael Scheurer, MPH, PhD, FACE: No relevant conflicts of interest to declare.